Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 806-817

  Feng, Joy Y ^a   Xu, Yili ^a   Barauskas, Ona ^a   Perry, Jason K ^a   Ahmadyar, Shekeba ^a   Stepan, George ^a   Yu, Helen ^a   Babusis, Darius ^a   Park, Yeojin ^a   McCutcheon, Krista ^a   Perron, Michel ^a   Schultz, Brian E ^a   Sakowicz, Roman ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 2',3' DIDEOXYGUANOSINE TRIPHOSPHATE; 4' AZIDOCYTIDINE; ALPHA AMANITIN; ANTIVIRUS AGENT; APHIDICOLIN; BALAPIRAVIR; BMS 986094; DNA POLYMERASE; FLUOROURACIL; GUANOSINE DERIVATIVE; IDX 184; MERICITABINE; MITOCHONDRIAL DNA; MITOCHONDRIAL DNA POLYMERASE; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RNA; MITOCHONDRIAL RNA POLYMERASE; NUCLEOSIDE; NUCLEOTIDE INHIBITOR; OXYGEN; RIBOSE; RNA POLYMERASE; SOFOSBUVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2'-FLUORO-2'-METHYL-3',5'-DIISOBUTYRYLDEOXYCYTIDINE; DEOXYCYTIDINE; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE GAMMA; DNA DIRECTED RNA POLYMERASE; GUANOSINE PHOSPHATE; INX 08189; RNA; RNA, MITOCHONDRIAL;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HEPATITIS C VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; OXYGEN CONSUMPTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; VIRUS STRAIN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DEOXYCYTIDINE; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; GUANOSINE MONOPHOSPHATE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MITOCHONDRIA; NUCLEOSIDES; OXYGEN CONSUMPTION; PROTEIN BIOSYNTHESIS; RNA; SOFOSBUVIR; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84957927232     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01922-15     Document Type: Article

References (46)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
2. Marks KM, Jacobson IM. 2012. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir Ther 17:1119-1131. http://dx.doi.org/10.3851/IMP2424.
3. Nelson DR. 2011. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 31(Suppl 1):S53-S57. http://dx.doi.org/10.1111/j.1478-3231.2010.02391.x.
4. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Najera I. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 61:1205-1216. http://dx.doi.org/10.1093/jac/dkn085.
5. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52:1604-1612. http://dx.doi.org/10.1128/AAC.01317-07.
6. Brown NA. 2009. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I. Nucleoside analogues. Expert Opin Invest Drugs 18:709-725. http://dx.doi.org/10.1517/13543780902854194.
7. Pharmasset. 16 December 2011. Pharmasset announces intent to amend Quantum trial. Press release. Pharmasset, Princeton, NJ. http://www.sec.gov/Archives/edgar/data/1301081/000119312511344160/d270472dex991.htm.
8. Idenix Pharmaceuticals. 4 February 2013. Idenix Pharmaceuticals provides update on IDX184 and IDX19368 development programs. General release. Idenix Pharmaceuticals, Cambridge, MA. http://globenewswire.com/news-release/2013/02/04/520696/10020506/en/Idenix-Pharmaceuticals-Provides-Update-on-IDX184-and-IDX19368-Development-Programs.html.
9. Bristol-Myers Squibb. 23 August 2012. Bristol-Myers Squibb discontinues development of BMS-986094, an investigational NS5B nucleotide for the treatment of hepatitis C. Press release. Bristol-Myers Squibb, New York, NY. http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa.
10. Vertex Pharmaceuticals Incorporated. July 25 2013. Vertex provides update on ongoing all-oral studies of VX-135 in hepatitis C. Press release. Vertex Pharmaceuticals, Inc., Cambridge, MA. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=780456.
11. Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53:926-934. http://dx.doi.org/10.1128/AAC.01032-08.
12. Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, Kireeva ML, Cho A, Perry J, Vela JE, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson BR, Gnatt A, Kashlev M, Zhong W, Cameron CE. 2012. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 8:e1003030. http://dx.doi.org/10.1371/journal.ppat.1003030.
13. Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, Eng S, Tirunagari N, Peng B, Yu M, Tian Y, Lee YJ, Stepan G, Lagpacan LL, Jin D, Hung M, Ku KS, Han B, Kitrinos K, Perron M, Birkus G, Wong KA, Zhong W, Kim CU, Carey A, Cho A, Ray AS. 2014. Inhibition of Hepatitis C VIRUS REPlication by GS-6620, a Potent C-Nucleoside Monophosphate Prodrug. Antimicrob Agents Chemother 58:1930-1942. http://dx.doi.org/10.1128/AAC.02351-13.
14. Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, McKinsey TA. 2004. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 24:10636-10649. http://dx.doi.org/10.1128/MCB.24.24.10636-10649.2004.
15. Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Schoeters G, Sibiril Y, Van Den Heuvel R, Gribaldo L. 2003. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355-367. http://dx.doi.org/10.1093/toxsci/kfg188.
16. Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR, Ray AS. 2009. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm 6:1145-1151. http://dx.doi.org/10.1021/mp900036s.
17. Hannan RD, Hempel WM, Cavanaugh A, Arino T, Dimitrov SI, Moss T, Rothblum L. 1998. Affinity purification of mammalian RNA polymerase I. Identification of an associated kinase. J Biol Chem 273:1257-1267. http://dx.doi.org/10.1074/jbc.273.2.1257.
18. Wang Z, Roeder RG. 1997. Three human RNA polymerase III-specific subunits form a subcomplex with a selective function in specific transcription initiation. Genes Dev 11:1315-1326. http://dx.doi.org/10.1101/gad.11.10.1315.
19. Clarke MO, Mackman R, Byun D, Hui H, Barauskas O, Birkus G, Chun BK, Doerffler E, Feng J, Karki K, Lee G, Perron M, Siegel D, Swaminathan S, Lee W. 2015. Discovery of β-D-2′-deoxy-2′-α-fluoro-4′-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. Bioorg Med Chem Lett 25:2484-2487. http://dx.doi.org/10.1016/j.bmcl.2015.04.073.
20. Roeder RG. 1974. Multiple forms of deoxyribonucleic acid-dependent ribonucleic acid polymerase in Xenopus laevis. Isolation and partial characterization. J Biol Chem 249:241-248.
21. Rothblum LI, Mamrack PM, Kunkle HM, Olson MO, Busch H. 1977. Fractionation of nucleoli. Enzymatic and two-dimensional polyacrylamide gel electrophoretic analysis. Biochemistry 16:4716-4721.
22. Beeson CC, Beeson GC, Schnellmann RG. 2010. A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 404:75-81. http://dx.doi.org/10.1016/j.ab.2010.04.040.
23. Nadanaciva S, Rana P, Beeson GC, Chen D, Ferrick DA, Beeson CC, Will Y. 2012. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J Bioenerg Biomembr 44:421-437. http://dx.doi.org/10.1007/s10863-012-9446-z.
24. Dranka BP, Benavides GA, Diers AR, Giordano S, Zelickson BR, Reily C, Zou L, Chatham JC, Hill BG, Zhang J, Landar A, Darley-Usmar VM. 2011. Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic Biol Med 51:1621-1635. http://dx.doi.org/10.1016/j.freeradbiomed.2011.08.005.
25. Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG. 2011. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 71:1418-1430. http://dx.doi.org/10.1158/0008-5472.CAN-10-1728.
26. Yin YW, Steitz TA. 2004. The structural mechanism of translocation and helicase activity in T7 RNA polymerase. Cell 116:393-404. http://dx.doi.org/10.1016/S0092-8674(04)00120-5.
27. Ringel R, Sologub M, Morozov YI, Litonin D, Cramer P, Temiakov D. 2011. Structure of human mitochondrial RNA polymerase. Nature 478:269-273. http://dx.doi.org/10.1038/nature10435.
28. Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD, Smee DF, Frick DN, Heck JA, Wang P, Nagarathnam D, Ross BS, Sofia MJ, Otto MJ, Furman PA. 2010. PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 54:3187-3196. http://dx.doi.org/10.1128/AAC.00399-10.
29. Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, Clarke M, Doerffler E, Byun D, Wang T, Babusis D, Carey AC, German P, Sauer D, Zhong W, Rossi S, Fenaux M, McHutchison JG, Perry J, Feng J, Ray AS, Kim CU. 2014. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 57:1812-1825. http://dx.doi.org/10.1021/jm400201a.
30. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF. 2015. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 62:409-416. http://dx.doi.org/10.1002/hep.27488.
31. De Clercq E. 2011. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 51:1-24. http://dx.doi.org/10.1146/annurev-pharmtox-010510-100228.
32. Anderson KS. 2002. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase. Biochim Biophys Acta 1587:296-299. http://dx.doi.org/10.1016/S0925-4439(02)00092-3.
33. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099-1105. http://dx.doi.org/10.1056/NEJM199510263331702.
34. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276:40847-40857. http://dx.doi.org/10.1074/jbc.M106743200.
35. Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, de Courten-Myers G, Ascenzi MA, Hornbuckle WE, Gerin JL, Tennant BC. 1997. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77-87.
36. Lewis W, Day BJ, Copeland WC. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2:812-822. http://dx.doi.org/10.1038/nrd1201.
37. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. 1994. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 38:1824-1828. http://dx.doi.org/10.1128/AAC.38.8.1824.
38. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ, Carroll SS. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48:3944-3953. http://dx.doi.org/10.1128/AAC.48.10.3944-3953.2004.
39. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. 2007. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97:539-547. http://dx.doi.org/10.1093/toxsci/kfm052.
40. Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters CR, Wang J, Williams K, Patti JM, Henson G, Madela K, Aljarah M, Gilles A, McGuigan C. 2011. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 55:1843-1851. http://dx.doi.org/10.1128/AAC.01335-10.
41. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. 2011. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 55:76-81. http://dx.doi.org/10.1128/AAC.01101-10.
42. White AJ. 2001. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 77:158-173. http://dx.doi.org/10.1136/sti.77.3.158.
43. Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Micolochick Steuer H, Keilman M, Zennou V, Bourne N, Veselenak RL, Chang W, Ross BS, Du J, Otto MJ, Sofia MJ. 2011. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res 91:120-132. http://dx.doi.org/10.1016/j.antiviral.2011.05.003.
44. Domanski MJ, Sloas MM, Follmann DA, Scalise PP, III, Tucker EE, Egan D, Pizzo PA. 1995. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 127:137-146. http://dx.doi.org/10.1016/S0022-3476(95)70275-X.
45. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD. 1992. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 116:311-313. http://dx.doi.org/10.7326/0003-4819-116-4-311.
46. Suarez CR, Ow EP. 1992. Chloramphenicol toxicity associated with severe cardiac dysfunction. Pediatr Cardiol 13:48-51.